Castle Biosciences, Inc.
CSTLNASDAQHealthcare● Active
$20.12
$-0.89(-4.24%)
Market Cap$610238634
P/E Ratio—
52W High$44.28
52W Low$14.59
Castle Biosciences, Inc. (CSTL) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
CSTL · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 6, 2026EPS Actual
-$0.49
Est. -$0.49 · +0.0%
Revenue
$0.08B
Est. $0.08B · +6.3%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 6, 2026
After Market Close
▲ Beat Revenue🔥 4-Quarter EPS Beat Streak
CSTL reports quarterly as a NASDAQ-listed Medical - Diagnostics & Research company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 3, 2026 | -$0.38 | — | — | — | $0.09B | — |
| — Q2 FY2026 | May 6, 2026 | -$0.49 | -$0.49 | +0.0% | $0.08B | $0.08B | +6.3% |
| ▲ Q1 FY2026 | Feb 26, 2026 | -$0.23 | -$0.08 | +65.2% | $0.09B | $0.08B | +8.9% |
| ▲ Q4 FY2025 | Nov 3, 2025 | -$0.34 | -$0.02 | +94.1% | $0.08B | $0.08B | +3.3% |
| ▲ Q3 FY2025 | Aug 4, 2025 | -$0.51 | $0.15 | +129.4% | $0.09B | $0.07B | +26.8% |
| ▼ Q2 FY2025 | May 5, 2025 | -$0.08 | -$0.20 | -150.0% | $0.09B | $0.07B | +22.5% |
| ▲ Q1 FY2025 | Feb 27, 2025 | -$0.04 | $0.32 | +900.0% | $0.09B | $0.08B | +2.9% |
| ▲ Q4 FY2024 | Nov 4, 2024 | -$0.06 | $0.08 | +233.3% | $0.09B | $0.08B | +6.5% |
Q3 FY2026
Aug 3, 2026
EPS Actual
—
EPS Est.
-$0.38
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 6, 2026
EPS Actual
-$0.49
EPS Est.
-$0.49
EPS Surpr.
+0.0%
Revenue
$0.08B
Q1 FY2026
Feb 26, 2026Beat
EPS Actual
-$0.08
EPS Est.
-$0.23
EPS Surpr.
+65.2%
Revenue
$0.09B
Q4 FY2025
Nov 3, 2025Beat
EPS Actual
-$0.02
EPS Est.
-$0.34
EPS Surpr.
+94.1%
Revenue
$0.08B
Q3 FY2025
Aug 4, 2025Beat
EPS Actual
$0.15
EPS Est.
-$0.51
EPS Surpr.
+129.4%
Revenue
$0.09B
Q2 FY2025
May 5, 2025Miss
EPS Actual
-$0.20
EPS Est.
-$0.08
EPS Surpr.
-150.0%
Revenue
$0.09B
Q1 FY2025
Feb 27, 2025Beat
EPS Actual
$0.32
EPS Est.
-$0.04
EPS Surpr.
+900.0%
Revenue
$0.09B
Q4 FY2024
Nov 4, 2024Beat
EPS Actual
$0.08
EPS Est.
-$0.06
EPS Surpr.
+233.3%
Revenue
$0.09B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-0.13 | $-0.12 | $-0.12 | 2 |
| Q3 FY2027 | $-0.16 | $-0.15 | $-0.15 | 1 |
| Q2 FY2027 | $-0.25 | $-0.25 | $-0.24 | 1 |
| Q1 FY2027 | $-0.43 | $-0.43 | $-0.42 | 2 |
| Q4 FY2026 | $-0.28 | $-0.28 | $-0.28 | 2 |
| Q3 FY2026 | $-0.30 | $-0.29 | $-0.29 | 4 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.1B | $0.1B | $0.1B | 3 |
| Q3 FY2027 | $0.1B | $0.1B | $0.1B | 2 |
| Q2 FY2027 | $0.1B | $0.1B | $0.1B | 2 |
| Q1 FY2027 | $0.1B | $0.1B | $0.1B | 3 |
| Q4 FY2026 | $0.1B | $0.1B | $0.1B | 3 |
| Q3 FY2026 | $0.1B | $0.1B | $0.1B | 4 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 6, 2026 | +0.0% | $24.60 | $24.75 | +0.61% |
| ▲ Q1 FY2026 | Feb 26, 2026 | +65.2% | $30.83 | $31.88 | +3.41% |
| ▲ Q4 FY2025 | Nov 3, 2025 | +94.1% | $25.50 | $25.99 | +1.92% |
| ▲ Q3 FY2025 | Aug 4, 2025 | +129.4% | $14.65 | $15.32 | +4.57% |
| ▼ Q2 FY2025 | May 5, 2025 | -150.0% | $19.35 | $18.75 | -3.10% |
| ▲ Q1 FY2025 | Feb 27, 2025 | +900.0% | $26.04 | $25.28 | -2.92% |
| ▲ Q4 FY2024 | Nov 4, 2024 | +233.3% | $33.15 | $33.64 | +1.48% |
| ▲ Q3 FY2024 | Aug 5, 2024 | +214.8% | $22.28 | $21.85 | -1.93% |
Q2 FY2026+0.61%
Report Date
May 6, 2026
EPS Beat/Miss
+0.0%
Price Before
$24.60
Price After
$24.75
Q1 FY2026+3.41%
Report Date
Feb 26, 2026
EPS Beat/Miss
+65.2%
Price Before
$30.83
Price After
$31.88
Q4 FY2025+1.92%
Report Date
Nov 3, 2025
EPS Beat/Miss
+94.1%
Price Before
$25.50
Price After
$25.99
Q3 FY2025+4.57%
Report Date
Aug 4, 2025
EPS Beat/Miss
+129.4%
Price Before
$14.65
Price After
$15.32
Q2 FY2025-3.10%
Report Date
May 5, 2025
EPS Beat/Miss
-150.0%
Price Before
$19.35
Price After
$18.75
Q1 FY2025-2.92%
Report Date
Feb 27, 2025
EPS Beat/Miss
+900.0%
Price Before
$26.04
Price After
$25.28
Q4 FY2024+1.48%
Report Date
Nov 4, 2024
EPS Beat/Miss
+233.3%
Price Before
$33.15
Price After
$33.64
Q3 FY2024-1.93%
Report Date
Aug 5, 2024
EPS Beat/Miss
+214.8%
Price Before
$22.28
Price After
$21.85
Avg Beat Reaction+1.02%
Avg Miss Reaction-3.10%
Beat Rate7 / 8 quarters
Largest Move+4.57% (Q3 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: CSTL ends December
Castle Biosciences, Inc. (CSTL) most recently reported earnings on May 6, 2026 for Q2 FY2026, posting EPS of $-0.49 (in line with the analyst consensus of $-0.49). CSTL has beaten EPS estimates for 4 consecutive quarters. The next CSTL earnings date is expected around September 1, 2026.
Each quarter, investors track CSTL earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. CSTL revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
CSTL's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
CSTL earnings · 4 questionsCastle Biosciences, Inc.'s next earnings report is expected around September 1, 2026. CSTL typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; CSTL historically reports after market close (AMC).
CSTL earnings datewhen is CSTL earningsCSTL next earnings datewhen does CSTL report earningsCSTL earnings calendar
▸ Source: FMP · Castle Biosciences, Inc. SEC filings · US GAAP · Castle Biosciences, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026